Potency of clinical group B streptococcal conjugate vaccines

被引:16
作者
Paoletti, LC [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA
关键词
maternal vaccination; neonatal infections; glycoconjugates; women's health; perinatal infections; group B streptococci; potency; stability; exclusion criteria;
D O I
10.1016/S0264-410X(00)00437-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The potency of clinical group B streptococcal (GBS) capsular polysaccharide-protein conjugate vaccines has been assessed with use of a mouse maternal vaccination-neonatal pup challenge model of GBS disease. Two of the three conjugated GBS vaccines bottled as liquid preparations showed a potency reduction from 100% to less than or equal to 50% in 3 years; whereas all six vaccines bottled as lyophilized preparations with sucrose excipient exhibited no loss of potency Juring the same span of time. A reconstituted GBS conjugate vaccine remained potent and antigenically intact after 31 days' storage at 2-8 degreesC. These data suggest that lyophilization in the presence of sucrose extends the potency of GBS conjugate vaccines. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2118 / 2126
页数:9
相关论文
共 17 条
[1]   Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib [J].
Baker, CJ ;
Paoletti, LC ;
Wessels, MR ;
Guttormsen, HK ;
Rench, MA ;
Hickman, ME ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :142-150
[2]  
BAKER CJ, 2000, IN PRESS J INFECT DI
[3]   Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine [J].
Kaspar, DL ;
Paoletti, LC ;
Wessels, MR ;
Guttormsen, HK ;
Carey, VJ ;
Jennings, HJ ;
Baker, CJ .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (10) :2308-2314
[4]   SYNTHESIS AND IMMUNOLOGICAL PROPERTIES OF CONJUGATES COMPOSED OF GROUP-B STREPTOCOCCUS TYPE-III CAPSULAR POLYSACCHARIDE COVALENTLY BOUND TO TETANUS TOXOID [J].
LAGERGARD, T ;
SHILOACH, J ;
ROBBINS, JB ;
SCHNEERSON, R .
INFECTION AND IMMUNITY, 1990, 58 (03) :687-694
[5]   MATERNAL IMMUNIZATION OF MICE WITH GROUP-B STREPTOCOCCAL TYPE-III POLYSACCHARIDE-BETA C-PROTEIN CONJUGATE ELICITS PROTECTIVE ANTIBODY TO MULTIPLE SEROTYPES [J].
MADOFF, LC ;
PAOLETTI, LC ;
TAI, JY ;
KASPER, DL .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (01) :286-292
[6]   Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice [J].
Paoletti, LC ;
Pinel, J ;
Rodewald, AK ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (05) :1237-1239
[7]   Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII [J].
Paoletti, LC ;
Pinel, J ;
Johnson, KD ;
Reinap, B ;
Ross, RA ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :892-895
[8]   Immunogenicity of group B Streptococcus type III polysaccharide tetanus toxoid vaccine in baboons [J].
Paoletti, LC ;
Kennedy, RC ;
Chanh, TC ;
Kasper, DL .
INFECTION AND IMMUNITY, 1996, 64 (02) :677-679
[9]   Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate [J].
Paoletti, LC ;
Pinel, J ;
Kennedy, RC ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (02) :653-658
[10]   GROUP-B STREPTOCOCCUS TYPE-II POLYSACCHARIDE-TETANUS TOXOID CONJUGATE VACCINE [J].
PAOLETTI, LC ;
WESSELS, MR ;
MICHON, F ;
DIFABIO, J ;
JENNINGS, HJ ;
KASPER, DL .
INFECTION AND IMMUNITY, 1992, 60 (10) :4009-4014